Larry Wray Email & Phone Number

Advising a startup in the single cell analysis space.

E-Sana is developing a point-of-care (POC) diagnostics platform using ion sensitive transistors, which detect antibody-antigen binding. The initial products will target infectious disease and allow for rapid, low cost, early diagnosis, with a targeted therapeutic approach at the point of need.

San Francisco, Ca, Us

Project Zygote, the digital health pre-accelerator, brokers relationships among various healthcare and tech entrepreneurs and takes them through a structured curriculum to vet and develop new health-tech innovations in the earliest stages to unbreak healthcare.The goal is to prepare digital-health startups to gain acceptance into full-fledged accelerator or incubator programs and increase the likelihood of truly improving healthcare performance and outcomes.I was pleased to serve as an advisor for the Fall 2017 Cohort.

Montreal, Quebec, Ca

Virtual Rehab leverages the advancements in Virtual and Augmented Reality technology to reduce the number of repeated offenses and re-incarceration rates worldwide.Virtual Rehab is developing a powerful tool (provisionally patented) which would rehabilitate rather than just punish. The scope of this tool includes Formal Education, Vocational Job Training, Psychological Rehabilitation, and Correctional Services Rehabilitation. Virtual Rehab’s services will extend to inmates, correctional officers, rehab centers, children-in-need, along with other verticals in the future.

New York, Ny, Us

GLG Council Members are invited experts in GLG's worldwide network and include business leaders, scientists, academics, former public sector leaders and subject mater specialists. Consulting GLC's clients in healthcare, with a focus on in vitro diagnostics (IVD) and life science tools.

I am helping early stage and established companies, universities and investors commercialize new technologies as clinical diagnostic or life science tools, products and services. Working with clients, I help them define applications for their technologies, which solve problems and address unmet needs, de-risk the process and maximize success of an on-time, within budget launch. Arrangements are flexible and can either be in a consulting or advisory capacity or interim operating management roles. Services include technology assessment and due diligence, opportunity assessments and strategy, product development, quality systems, manufacturing processes and supply chain, technical support of clinical studies and regulatory submissions, and project and program management.T: 925-596-4344E: larry@wrayivd.comwww.wrayivd.com

Emeryville, Ca, Us

Clients have included early stage and established companies and NGOs, with a focus on the commercialization of new technologies as clinical diagnostics (IVDs), both laboratory based and point of care.

San Leandro, California, Us

Next generation mobile diagnostics to enable earlier and more accurate testing in hospital and pre-hospital settings, built on a strong leadership position in nanotechnology. I was attracted to the opportunity to commercialize technology which would enable bringing new products to market addressing significant unmet needs in healthcare. In conjunction with this, I instituted a number of improvements to enhance the product development process, with the objectives of reducing time to market and improving the performance and cost structure of the products. These included strengthening core team skill sets and organization, improvements in experimental design, supply chain, and project management, resulting in two products readied for clinical trials.

Shelton, Ct, Us

Global responsibility for R&D and project portfolio management (PPM) with the Diagnostics Division, multiple domestic and international sites, products (IVD) as well as CLIA certified service laboratories.The focus is on maternal, fetal, and newborn health, along with a broad emerging markets portfolio. The business also includes traditional in vitro diagnostic products, nucleic acid extraction products, NGS, and a cord blood banking business. The product line includes instruments, reagents and software/ informatics, with immunoassays, molecular diagnostics and mass spectrometry.I joined the company to build and lead a global R&D organization to leverage assets across several sites, with a number of accomplishments: • Established a new global R&D organization composed of 8 sites, 5 in the U.S. and sites in China, Finland and Germany with approximately 250 personnel.• Established a Project Management Office (PMO) to establish best practices, harmonize, and manage product development across the organization.• Implemented a number of process improvements for review and decision making as the Chair of the Business Investment Committee (BIC), with responsibility for approval of new projects and ongoing review of existing projects through the PACE stage gate process.• Led the development and launch of over 60 new instrument, reagent, and software products, supporting four businesses, in both domestic and emerging markets, continuously reducing cycle times and costs, while improving quality.• Implemented the development of an R&D strategy on an ongoing basis, as an integral part of the overall diagnostics strategic planning process.

Us

Established to commercialize and deliver proteomic biomarker discovery and validation technology, developed at MD Anderson Cancer Center, to the pharmaceutical sector. Nine companion diagnostic alliances (patient stratification and pharmacodynamic biomarker discovery/validation), including Phase I-II clinical trial support). Position focused on the development of an initial oncology companion diagnostics product, and included working with alliance partners on study planning, execution, data review and reports, IP management, project planning, and fundraising.

GeneWEAVE is taking on drug-resistant bacteria – modern medicine’s biggest challenge. We use our novel Smarticles™ technology to build solutions that give healthcare providers around the world the tools they need to guide treatment and keep patients safe from the threat of bacterial infections. Roche Molecular Diagnostics acquired GeneWEAVE in August 2015.

Molecular diagnostics product development for infectious disease, genetic disease, and oncology. Platforms included real time PCR and DNA sequencing.In this role, I managed the product development organization and, as a member of the Product Action Committee (PAC), provided strategic direction and decision making for overall company strategies for new product development. Specific accomplishments included: • Revamped procedures for planning, execution, and documentation of development studies conducted under design control and in compliance with quality system requirements, resulting in reduced business and compliance risk and accelerated development times.• Introduced two new FDA approved and CE marked products for HIV mutation drug resistance detection.• Developed assays for additional (integrase, gp41) mutation drug resistance in conjunction with the ViroSeq product.• Developed a multiplex real time PCR assay for Avian Flu, Flu A, and Flu B.• Developed a 100-plex oligonucleotide ligation assay (OLA) for cystic fibrosis mutation detection on the Luminex platform.

Tucson, Arizona, Us

Reagent and product development with IHC (immunohistochemistry) and ISH (in situ hybridization) on automated platforms.I was recruited to develop an internal capability for reagent development to improve margins and secure supply chain and in conjunction with this:• Authored and implemented critical reagents strategy, resulting in secure supply channels, improved quality, and significantly (20-200%) improved manufacturing margins for core product components.• Staffed and developed organization with core competencies to execute reagent strategy.• Negotiated and managed licensing and partnering agreements to access monoclonal antibodies, resulting in 20 licensed hybridoma cell lines.• Designed and oversaw construction of new cGMP facility for cell culture, reagent development and production and established associated processes and systems. • Acquired in excess of 60,000 fixed human tissue specimens and established tissue bank program to support ongoing reagent development.• Launched five IHC IVD products (including one PMA and two 510ks) as a breast cancer panel, representing 30% of reagent product sales.

Abbott Park, Illinois, Us

Various technical and management positions in reagent and product development, project and program management, manufacturing, and business development. Infectious disease, abused drugs and toxicology, and metabolic disease. Immunoassays and molecular diagnostics.Highlights include:• Developed strategy, business planning, technology scouting and acquisition, and managed a new business venture for osteoporosis and degenerative disease diagnostics, with three new products introduced.• As R&D Manager for Abused Drugs and Toxicology, launched 12 products on the AxSYM automated immunoanalyzer, with reduced time to market and $1M development cost savings.• Managed technical support and process development for the Molecular Diagnostics business, supporting both products on the market and new product development, and established the manufacturing facility.• Established and managed the core monoclonal antibody development program for the Diagnostics Division, supporting product development for 12 businesses.• Developed and launched a new generation hepatitis B immunoassay product for blood bank screening, the largest selling product in the Diagnostics Division at the time.

Washington, Dc, Us

Nih Postdoctoral Fellow, Human Genetics

Ph.D., Genetics

M.S, Health And Medical Sciences (Genetics Counseling)

B.A., Chemistry